Drug Trial Radar · NCT00418171
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18,239
Actual
Start
Feb 2002
Primary completion
Not stated
Study completion Apr 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.
Conditions
- Schizophrenia
Interventions
ZiprasidoneDrug
OlanzapineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality within 12 months.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
San Bernardino, California
Pfizer Investigational Site
‘Aiea, Hawaii
Pfizer Investigational Site
Schaumburg, Illinois
Pfizer Investigational Site
Grants Pass, Oregon
Pfizer Investigational Site
White Hall, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.